Research Index
Davunetide (NAP/AL-108) Research Index
PSI surfaces 50 peer-reviewed studies on Davunetide (NAP/AL-108), prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.
Schaak A, Walker M, Worden B et al.
Epilepsy Res·2026·Animal·PubMed →
Drosophila wing is a high-throughput and versatile screening tool for Tau-mediated disease mechanisms and drug discovery.
Ramirez-Moreno M, Cooper AS, Lian T et al.
Dis Model Mech·2026·Animal·Neuroprotection·PubMed →
Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration.
García-Castro J, VandeVrede L, Donohue MC et al.
J Prev Alzheimers Dis·2026·Animal·PubMed →
Davunetide promotes structural and functional recovery of the injured spinal cord by promoting autophagy.
Chen Y, Liu R, Cai W et al.
Neural Regen Res·2026·Animal·PubMed →
Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG).
Gozes I, Blatt J, Guz LS
Transl Psychiatry·2025·Human·Neuroprotection·PubMed →
Brain Networks Route Neurodegeneration Patterns in Patients with Progressive Supranuclear Palsy.
Palleis C, Quattrone A, Dehsarvi A et al.
Mov Disord·2025·Human·PubMed →
The ADNP-Mediated Transcriptome Response to Ketamine Impairs the Cytoskeletal Protein Axis.
D'Incal CP, Mateiu L, De Man K et al.
J Mol Neurosci·2025·Animal·PubMed →
Brain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.
Quattrone A, Franzmeier N, Huppertz HJ et al.
Mov Disord·2025·Animal·PubMed →
Editorial: A Child with ADNP Syndrome: A Case Study of Symptoms, Diagnostic Process and Innovative Behavioral Intervention Modes.
Holec M, Gozes I
J Mol Neurosci·2025·Animal·PubMed →
A 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.
Dam T, Yang L, Gillis C et al.
Nat Commun·2025·Animal·PubMed →
Microtubule-Targeting NAP Peptide-Ru(II)-polypyridyl Conjugate As a Bimodal Therapeutic Agent for Triple Negative Breast Carcinoma.
Chatterjee A, Sarkar S, Bhattacharjee S et al.
J Am Chem Soc·2025·Animal·PubMed →
ADNP is essential for sex-dependent hippocampal neurogenesis, through male unfolded protein response and female mitochondrial gene regulation.
Shapira G, Karmon G, Hacohen-Kleiman G et al.
Mol Psychiatry·2025·Animal·Neuroprotection·PubMed →
Beneficial effects of CHF6467, a modified human nerve growth factor, in experimental neonatal hypoxic-ischaemic encephalopathy.
Landucci E, Mango D, Carloni S et al.
Br J Pharmacol·2025·Animal·Neuroprotection·PubMed →
Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease.
Gozes I, Blatt J, Lobyntseva A
Transl Psychiatry·2024·Human·PubMed →
Concomitant Medications for Progressive Supranuclear Palsy: A Secondary Analysis of a Randomized Clinical Trial.
Iyer JM, Gunzler D, Lang AE et al.
JAMA Neurol·2024·Human·PubMed →
Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes.
Kraskovskaya N, Linkova N, Sakhenberg E et al.
Int J Mol Sci·2024·Animal·Tissue Remodeling, Neuroprotection, Longevity·PubMed →
Transcriptomic alterations in APP/PS1 mice astrocytes lead to early postnatal axon initial segment structural changes.
Benitez MJ, Retana D, Ordoñez-Gutiérrez L et al.
Cell Mol Life Sci·2024·Animal·Neuroprotection·PubMed →
Sex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity.
Toren Y, Ziv Y, Sragovich S et al.
J Mol Neurosci·2024·Animal·PubMed →
Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
Quattrone A, Franzmeier N, Huppertz HJ et al.
Mov Disord·2024·Animal·PubMed →
Integrated ribosome and proteome analyses reveal insights into sevoflurane-induced long-term social behavior and cognitive dysfunctions through ADNP inhibition in neonatal mice.
Liang LR, Liu B, Cao SH et al.
Zool Res·2024·Animal·PubMed →
ADNP dysregulates methylation and mitochondrial gene expression in the cerebellum of a Helsmoortel-Van der Aa syndrome autopsy case.
D'Incal C, Van Dijck A, Ibrahim J et al.
Acta Neuropathol Commun·2024·Animal·PubMed →
Longitudinal Genotype-Phenotype (Vineland Questionnaire) Characterization of 15 ADNP Syndrome Cases Highlights Mutated Protein Length and Structural Characteristics Correlation with Communicative Abilities Accentuated in Males.
Levine J, Lobyntseva A, Shazman S et al.
J Mol Neurosci·2024·Animal·PubMed →
Tau, ADNP, and sex.
Gozes I
Cytoskeleton (Hoboken)·2024·Animal·PubMed →
Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
Gozes I, Shapira G, Lobyntseva A et al.
Transl Psychiatry·2023·Animal·PubMed →
NAP (Davunetide): The Neuroprotective ADNP Drug Candidate Penetrates Cell Nuclei Explaining Pleiotropic Mechanisms.
Ganaiem M, Gildor ND, Shazman S et al.
Cells·2023·Animal·Neuroprotection·PubMed →
A novel genomic mutation in ADNP leading to intellectual disability.
Gozes I
Eur J Hum Genet·2023·Animal·PubMed →
A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome.
Gozes I, Shazman S
Eur J Neurosci·2023·Animal·PubMed →
Nanoscopy and an extended lateral approach can improve the management of latero-central segments in tibial plateau fractures: a cadaveric study.
Behrendt P, Berninger MT, Thürig G et al.
Eur J Trauma Emerg Surg·2023·Animal·PubMed →
Distinct Impairments Characterizing Different ADNP Mutants Reveal Aberrant Cytoplasmic-Nuclear Crosstalk.
Ganaiem M, Karmon G, Ivashko-Pachima Y et al.
Cells·2022·Animal·PubMed →
Cu and Zn Interactions with Peptides Revealed by High-Resolution Mass Spectrometry.
Iavorschi M, Lupăescu AV, Darie-Ion L et al.
Pharmaceuticals (Basel)·2022·Animal·PubMed →
Rational Discovery of Microtubule-Stabilizing Peptides.
Úsuga-Acevedo B, García Y, Díaz CF et al.
J Chem Inf Model·2022·Animal·PubMed →
SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.
Ivashko-Pachima Y, Ganaiem M, Ben-Horin-Hazak I et al.
Mol Psychiatry·2022·Animal·PubMed →
STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimer's Disease: The Case of ADNP.
Gozes I, Shazman S
Front Endocrinol (Lausanne)·2022·Animal·PubMed →
A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments.
Wills AM, Pantelyat A, Espay A et al.
Mov Disord·2022·Animal·PubMed →
Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies.
Karmon G, Sragovich S, Hacohen-Kleiman G et al.
Biol Psychiatry·2022·Animal·PubMed →
Zinc Binding to NAP-Type Neuroprotective Peptides: Nuclear Magnetic Resonance Studies and Molecular Modeling.
Lupaescu AV, Mocanu CS, Drochioiu G et al.
Pharmaceuticals (Basel)·2021·Animal·PubMed →
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
VandeVrede L, Dale ML, Fields S et al.
Mov Disord Clin Pract·2020·Human·PubMed →
Associations Between Amantadine Usage, Gait, and Cognition in PSP: A post-hoc Analysis of the Davunetide Trial.
Dale ML, Brumbach BH, Boxer AL et al.
Front Neurol·2020·Animal·PubMed →
Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis.
Ivashko-Pachima Y, Gozes I
J Mol Neurosci·2020·Animal·Neuroprotection·PubMed →
An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.
Çakici N, van Beveren NJM, Judge-Hundal G et al.
Psychol Med·2019·Human·PubMed →
Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.
Brittain C, McCarthy A, Irizarry MC et al.
Parkinsonism Relat Disord·2019·Human·Neuroprotection·PubMed →
CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
Rojas JC, Bang J, Lobach IV et al.
Neurology·2018·Human·PubMed →
Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.
Höglinger GU, Schöpe J, Stamelou M et al.
Mov Disord·2017·Human·PubMed →
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale.
Hewer S, Varley S, Boxer AL et al.
Mov Disord·2016·Human·PubMed →
Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy.
Tsai RM, Lobach I, Bang J et al.
Parkinsonism Relat Disord·2016·Human·PubMed →
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Boxer AL, Lang AE, Grossman M et al.
Lancet Neurol·2014·Human·PubMed →
Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.
Sommer IE, van Westrhenen R, Begemann MJ et al.
Schizophr Bull·2014·Human·PubMed →
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
Morimoto BH, Schmechel D, Hirman J et al.
Dement Geriatr Cogn Disord·2013·Human·Cognitive Enhancement·PubMed →
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
Jarskog LF, Dong Z, Kangarlu A et al.
Neuropsychopharmacology·2013·Human·Cognitive Enhancement·PubMed →
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC, Buchanan RW, Keefe RS et al.
Schizophr Res·2012·Human·Neuroprotection·PubMed →